Alcohol-Associated Liver Disease: Experimental Approaches to Decipher Pathogenesis
Nov
12
2023
Ballroom A
-
Hynes Convention Center
2:00
- 3:30 PM EST
Description
This scientific session focuses on novel experimental approaches and molecular insights into the pathogenesis of Alcohol-Associated Liver Disease (ALD), exploring potential therapeutic targets for its treatment.
Abstracts
- EXPLORING THE ROLE OF X-BINDING PROTEIN-1 (XBP1) IN THE GUT- LIVER AXIS DURING ALCOHOL-RELATED LIVER DISEASE (ARLD)
- INTESTINAL ENDOGENOUS RETROVIRUSES PROMOTE ETHANOL-INDUCED LIVER DISEASE IN MICE
- ALCOHOL CONSUMPTION ACCELERATES HEPATIC MICROPLASTIC ACCUMULATION VIA IMPAIRED INTESTINAL MUCOSAL BARRIER
- GENERATION AND CHARACTERIZATION OF A HUMANIZED MOUSE MODEL OF ALCOHOL INDUCED STEATOSIS, INFLAMMATION AND FIBROSIS
- CHRONIC ETHANOL INSULT INCREASES HSD17beta13 ON HEPATOCELLULAR LIPID DROPLETS VIA A LOSS OF AN ASSOCIATED SEGREGASE p97/VCP TO PROMOTE HEPATIC STEATOSIS
- TARGETING IL-17RA IN HEPATOCYTES AS A NOVEL THERAPEUTICAL APPROACH FOR AALD USING GALNAC DELIVERY SYSTEM
Objectives
- Gain comprehensive insights into the pathogenesis of Alcohol-Associated Liver Disease through diverse experimental approaches, including investigations into endogenous retroviral elements, immune targeting, and cellular responses.
- Analyze potential therapeutic targets for ALD treatment, exploring the feasibility of targeting molecules involved in hepatic steatosis, inflammation, and fibrosis, and evaluate their potential clinical implications.
- Assess the impact of alcohol consumption on the gut-liver axis, intestinal mucosal barrier function, and hepatocellular lipid droplets, to better understand the complex interactions contributing to ALD development and progression.